Asia-Pacific journal of clinical oncology最新文献

{"title":"Access, Affordability, and Willingness to Undergo Screening Colonoscopy in a Low- and Middle-Income Country-A Cross-sectional Study From Sri Lanka.","authors":"Dileesha Wickramasinghe, Piyumi Perera, Dakshitha Praneeth Wickramasinghe","doi":"10.1111/ajco.70204","DOIUrl":"https://doi.org/10.1111/ajco.70204","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) incidence is rising rapidly across low- and middle-income countries (LMICs), yet most lack organised screening programmes. While colonoscopy is the diagnostic gold standard, its uptake depends not only on service availability but also on behavioural perceptions and health system design. Sri Lanka, an LMIC with a strong public health system but no national CRC screening programme, provides a relevant policy setting to examine these dynamics.</p><p><strong>Methods: </strong>A cross-sectional survey of 500 adults at the National Hospital of Sri Lanka assessed willingness to undergo screening colonoscopy. Sociodemographics, CRC-related knowledge, perceptions of benefit/harm, and cost considerations were evaluated using non-parametric tests and multivariable logistic regression.</p><p><strong>Results: </strong>Overall, 69.7% of participants were willing to undergo colonoscopy if recommended by a doctor; however, 42.7% would do so only if the procedure were free. Willingness was independently associated with belief that early detection improves outcomes (adjusted Odds Rate (aOR) 2.96, 95% confidence interval [CI] 1.94-4.53, p < 0.001) and fear of CRC (aOR 1.72, 95% CI 1.13-2.61, p = 0.012). Misconceptions about colonoscopy-related harm and fear of cancer diagnosis significantly reduced acceptance. Sociodemographic variables, education level, prior colonoscopy experience, and insurance status were not independently associated with willingness. Cost-related conditional willingness highlights substantial access barriers despite high stated acceptability.</p><p><strong>Conclusions: </strong>Among the variables examined, perceived benefit and affordability were important correlates of stated screening acceptability, while sociodemographic characteristics were not independently associated. Implementation requires strategies addressing affordability, capacity, and perceptions. A phased, publicly financed programme incorporating non-invasive testing and targeted communication may provide a feasible pathway for LMICs.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149134777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Rare Case of Acquired Haemophilia A Following Sigmoid Adenocarcinoma: Case Report and Literature Review.","authors":"Benjamin Reardon, Harini Haran, Jennifer Curnow","doi":"10.1111/ajco.70202","DOIUrl":"https://doi.org/10.1111/ajco.70202","url":null,"abstract":"<p><p>Acquired haemophilia A (AHA) is a rare autoimmune bleeding disorder resulting from the development of inhibitory autoantibodies against factor VIII (FVIII). Malignancy is a recognised association, although colorectal cancer remains an uncommon underlying cause. We report a 68-year-old woman with sigmoid adenocarcinoma who developed severe postoperative haemoperitoneum associated with progressive activated partial thromboplastin time prolongation, an initial FVIII activity of 52 IU/dL that subsequently declined to 2 IU/dL, and development of an FVIII inhibitor measuring 9.7 BU. The case highlights diagnostic challenges associated with AHA, particularly the risk of delayed diagnosis and the complexities of balancing immunosuppressive intensity alongside haemostatic therapy. We then present a review of current literature to guide management for this rare condition and emerging therapies.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149103497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Centralized Trophoblastic Care on Patients With Gestational Trophoblastic Neoplasia in a Statewide Service.","authors":"Chloe Ayres, Evelyn Werner, Vivienne Mallen, Marion Kember, Danelle Ward, Emma R Allanson","doi":"10.1111/ajco.70199","DOIUrl":"https://doi.org/10.1111/ajco.70199","url":null,"abstract":"<p><strong>Introduction: </strong>Rare cancers such as gestational trophoblastic neoplasia (GTN) should be managed in specialized centers, allowing for multidisciplinary team input, expert pathology review, consensus-based treatment and surveillance pathways, and improved patient survival and patient-reported outcomes.</p><p><strong>Methods: </strong>This retrospective study assessed the impact of centralized care implementation at a tertiary academic women's hospital on patients diagnosed and treated with GTN between 2021 and 2024 in Western Australia. Clinical outcomes compared 2 years pre-centralization (2021-2022) and 2 years post-centralization (2023-2024). The post-centralized patient experience was assessed via surveys.</p><p><strong>Results: </strong>A total of 36 patients with GTN were included: 20 pre-centralization and 16 post-centralization. Over the 4-year study period, 32 patients were categorized as low-risk, two were high-risk, and two had high-risk histology that precluded prognostic risk assignment. Centralization of care led to an improvement in identifying those who met the diagnostic criteria for GTN (65% vs. 100%, p = 0.011) and subsequent appropriate chemotherapeutic intervention, as well as better accuracy in the assignment of International Federation of Gynecology and Obstetrics (FIGO) stage (41% vs. 89%) and World Health Organization (WHO) prognostic score (46% vs. 82%). Methotrexate was favored as first-line chemotherapy for low-risk disease in both groups. There have been no relapses or deaths in either group to date. Centralization of care led to improved contraceptive counseling documentation (65% vs. 87.5%, p = 0.026) yet similar pregnancy rates. The patient experience with centralized care was positive.</p><p><strong>Conclusion: </strong>Although study numbers are small, this study supports the establishment of centralized centers for rare trophoblastic diseases.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149103482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ANZSA Annual Scientific Meeting","authors":"","doi":"10.1111/ajco.70181","DOIUrl":"https://doi.org/10.1111/ajco.70181","url":null,"abstract":"","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 S4","pages":"1-9"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149083925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Outcomes in Nasopharyngeal Carcinoma Treated With Intensity-Modulated Radiotherapy Versus 3D-Conformal Radiotherapy Techniques: A Single-Center Experience in a Developing Country.","authors":"Pooria Mousavi, Ali Kazemian, Ehsan Saraee, Mahdi Aghili, Sara Ahmadi, Kasra Kolahdouzan, Farshid Farhan, Amirhossein Ghasembagloo, Milad Payandeh, Mohammadreza Firouzifar, Farrokh Heidari, Marzieh Lashkari, Mohammad Babaei, Reza Ghalehtaki","doi":"10.1111/ajco.70196","DOIUrl":"https://doi.org/10.1111/ajco.70196","url":null,"abstract":"<p><strong>Background: </strong>Radiotherapy (RT) is the primary treatment for non-metastatic nasopharyngeal cancer (NPC). While intensity-modulated RT (IMRT) is preferred in wealthy regions, three-dimensional conformal RT (3D-CRT) remains common in resource-limited settings. This study evaluated IMRT versus 3D-CRT for NPC, focusing on survival, tumor control, and toxicities.</p><p><strong>Methods: </strong>This retrospective cohort study, performed at the Cancer Institute of Iran from 2007 to 2024, assessed individuals with non-metastatic nasopharyngeal carcinoma (NPC). Demographic data, treatment details, recurrence rates, metastasis, and survival information were obtained from medical records and follow-up telephone interviews. Complications associated with treatment were classified according to Common Terminology Criteria for Adverse Events v5.0 (2017). Statistical studies were conducted utilizing R software, accompanied with a p-value.</p><p><strong>Results: </strong>A total of 176 patients were enrolled, with 124 receiving 3D-CRT and 52 receiving IMRT. IMRT was associated with a significantly reduced incidence of dysphagia and with reduced severity of trismus, dysphagia, xerostomia, and hearing impairment. No significant differences were observed in the incidence or severity of neck stiffness or oral mucositis between the two groups. Concerning treatment results, no statistically significant differences were seen in disease-free survival or metastasis-free survival. The overall survival exhibited a non-significant trend favoring IMRT.</p><p><strong>Conclusion: </strong>IMRT markedly diminishes several treatment-associated complications in comparison to 3D-CRT; however, it does not provide a definitive survival advantage yet. Extended follow-up and prospective investigations are necessary to elucidate the disparities in long-term efficacy between the two approaches.</p><p><strong>Trial registration: </strong>Not applicable.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NRF2-Regulated Ferroptosis in Breast Cancer: Mechanisms, Resistance, and Therapeutic Opportunities.","authors":"Suleiman Ibrahim Mohammad, Asokan Vasudevan, Samreet Raizal Rodrigues, Rustam Turakulov, Mirza R Baig, Ozodbek Nematov, Navin Kumar Tailor, Divya Singhal, Priya Priyadarshini Nayak","doi":"10.1111/ajco.70195","DOIUrl":"https://doi.org/10.1111/ajco.70195","url":null,"abstract":"<p><p>Breast cancer remains a significant clinical challenge, particularly in triple‑negative breast cancer (TNBC), in which therapeutic resistance limits treatment efficacy. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has emerged as a promising strategy to overcome resistance in breast cancer. Among the principal nodulators of ferroptosis, NRF2 functions as a central antioxidant transcription factor that suppresses ferroptotic death by promoting glutathione metabolism and cystine uptake via SLC7A11/system Xc-, while also supporting GPX4-dependent lipid peroxide detoxification and iron-sequestering defenses such as FTH1/FTL. In breast cancer, aberrant NRF2 activation supports tumor progression, survival, stemness, immune evasion, and resistance to chemotherapy, radiotherapy, and targeted therapies. This review summarizes the molecular mechanisms by which NRF2 regulates ferroptosis, including KEAP1-NRF2 signaling, metabolic rewiring, iron homeostasis, lipid remodeling, and crosstalk with p53 and other stress-response pathways. We also highlight key regulators such as PRMT5, NUP62, NR5A2/NCOA3, miR-141-3p, DHODH, and ACSL4/ALOX enzymes that shape ferroptosis sensitivity. Furthermore, the review discusses emerging therapeutic approaches aimed at restoring ferroptotic vulnerability, including direct NRF2 inhibitors, natural products, metal-based compounds, repurposed drugs, and nanotechnology-enabled delivery systems. TNBC is specifically reliant on NRF2-driven antioxidant defenses to maintain redox homeostasis and resist ferroptotic stress, supporting its prioritization as a target population for NRF2-ferroptosis-based therapeutic methods. Collectively, targeting the NRF2-ferroptosis axis offers a compelling avenue for improving breast cancer treatment, especially in resistant and aggressive subtypes such as TNBC.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nimotuzumab Combined With Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma and Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis.","authors":"Chengzheng Bao, Yue Zhang, Xiang Fei, Kaifeng Ji, Ming Jia, Zhijun Li, Chao Bian","doi":"10.1111/ajco.70178","DOIUrl":"https://doi.org/10.1111/ajco.70178","url":null,"abstract":"<p><strong>Background: </strong>The benefit of adding nimotuzumab to chemoradiotherapy in head and neck squamous cell carcinoma is debated, and its role in nasopharyngeal carcinoma is even less defined. We evaluated the efficacy and safety of this combination in both diseases.</p><p><strong>Methods: </strong>We searched PubMed, Web of Science, Embase, Cochrane Library, China National Knowledge Infrastructure, Wanfang, and VIP databases through May 2025 for randomized controlled trials and propensity score-matched retrospective studies comparing nimotuzumab plus chemoradiotherapy with chemoradiotherapy alone. Random-effects models were used to pool hazard ratios and risk ratios with 95% confidence intervals.</p><p><strong>Results: </strong>Nine randomized trials (1142 patients) in non-nasopharyngeal head and neck squamous cell carcinoma showed that nimotuzumab improved overall survival (hazard ratio, 0.55; 95% confidence interval, 0.40-0.76) and progression-free survival (0.63; 0.53-0.76). Complete and objective response rates appeared higher with nimotuzumab, but both lost statistical significance after trim-and-fill adjustment for publication bias, indicating that these findings were largely driven by small-study effects. Grade 3-4 adverse events were comparable between arms. An exploratory analysis of nine nasopharyngeal carcinoma studies (2846 patients, predominantly retrospective) suggested a survival benefit.</p><p><strong>Conclusion: </strong>Nimotuzumab combined with chemoradiotherapy improves survival in head and neck squamous cell carcinoma without increasing severe toxicity. The nasopharyngeal carcinoma findings remain exploratory and require confirmation in prospective trials.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148975562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementation and Management of Cancer Clinical Quality Registries in Australia: A Qualitative Study.","authors":"Ashleigh R Sharman, Jonathan R Clark, Rebecca L Venchiarutti","doi":"10.1111/ajco.70182","DOIUrl":"https://doi.org/10.1111/ajco.70182","url":null,"abstract":"<p><strong>Background: </strong>In Australia, clinical quality registries (CQRs) for cancer care are becoming increasingly common, requiring integration across multiple sectors of the health system. This study sought to identify the means to successful implementation of CQRs in Australia by identifying barriers and facilitators of implementation and sustainability, and drivers of acceptability and feasibility.</p><p><strong>Methods: </strong>Online semi-structured interviews were conducted between May and June 2023 with directors, program leads, data managers, clinical champions, and other staff involved in implementation or management of CQRs across Australia. Barriers to and facilitators of implementing and delivering CQRs were mapped to themes of the Consolidated Framework for Implementation Research (CFIR) V.2.0.</p><p><strong>Results: </strong>Twenty stakeholders were interviewed. Participants identified a wide range of feasibility and implementation challenges for CQRs, with some questioning the ability of a CQR to facilitate clinical change. Participants strongly advocated for streamlined ethics and governance processes, appropriate technology infrastructure, sustainable funding, and workforce allocation. Stakeholders identified that the ongoing success of a CQR is influenced by lack of funding, low data quality, poor stakeholder motivation, and lack of training. Practical strategies to address challenges included developing a community of practice, clear training and guidelines, instating clinical champions, and appropriate pre-planning.</p><p><strong>Conclusion: </strong>Strong guidance to better support organizational oversight, training, management, and CQR operations will further strengthen and support successful future implementation. Practical strategies to address implementation challenges and to provide ongoing support for CQRs included developing a community of practice, clear training and guidelines, instating clinical champions, and appropriate pre-planning.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148954735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Voice of Asia: Provision of Patient-Centered Care in Oral Cavity Cancer: A Qualitative Study With Patients, Caregivers, and Healthcare Professionals in Five Asia-Pacific Regions","authors":"Edwin Pun Hui,&nbsp;Puma Sundaresan,&nbsp;Hye Ryun Kim,&nbsp;Khoi Tuan Nguyen,&nbsp;Tracey E Nicholls,&nbsp;Hai-Ling Teng,&nbsp;Yu-Chung Li,&nbsp;Ying Jie Yew,&nbsp;Regina Gowindah,&nbsp;Con Stylianou,&nbsp;Pei-Jen Lou","doi":"10.1111/ajco.70057","DOIUrl":"10.1111/ajco.70057","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Locoregionally advanced oral cavity squamous cell carcinoma (LA-OCSCC) imposes a high disease burden, significantly affecting patients’ quality of life. We aimed to identify unmet needs and challenges faced by patients, caregivers, and healthcare professionals (HCPs) in diagnosis and managing LA-OCSCC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In-depth interviews were conducted across Australia, Hong Kong, South Korea, Taiwan, and Vietnam with LA-OCSCC patients (<i>n </i>= 28), caregivers (<i>n</i> = 27), and HCPs (surgeons, clinical, radiation, and medical oncologists [<i>n</i> = 30]; nurses, case managers/coordinators, psychologists, speech therapists, dieticians, and dentists [<i>n </i>= 30]). Patients who received post-operative chemoradiotherapy for Stage III-IVB LA-OCSCC, their caregivers, and HCPs were eligible. The interview guide, design, and analysis were based on the Capability, Opportunity, Motivation, Behavior (COM-B) model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Major service gaps in timely diagnosis, treatment, patient-centered care, and therapeutic alliance were identified. Limited awareness of LA-OCSCC led to overlooked symptoms, delaying medical attention. General practitioners were perceived as less experienced in identifying LA-OCSCC symptoms accurately and promptly, with dentists being more informed. A shortage of nurses to support integrated multidisciplinary team discussions, patient education, and to relay patients’ needs to specialists, compromised patient-centric care. Psychotherapeutic services were scarce, with supportive care professionals overextending to bridge the gap.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study examined LA-OCSCC care management in five Asia-Pacific countries/territories with varying healthcare systems and infrastructure. Given LA-OCSCC's aggressive nature and high burden from disease and treatment, patients and caregivers require support beyond medical interventions. A multi-stakeholder approach with clinical and community care is essential to ensure a comprehensive and sustainable approach to patient-centered care within the different health systems.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 5","pages":"757-765"},"PeriodicalIF":2.1,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.70057","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145562405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Efficacy of Postoperative Adjuvant Nivolumab in High-Risk Urothelial Carcinoma: A Retrospective Comparative Study in an Asian Population","authors":"Ryunosuke Nakagawa,&nbsp;Renato Naito,&nbsp;Kouji Izumi,&nbsp;Takahiro Inaba,&nbsp;Ren Toriumi,&nbsp;Shuhei Aoyama,&nbsp;Taiki Kamijima,&nbsp;Hiroshi Kano,&nbsp;Tomoyuki Makino,&nbsp;Suguru Kadomoto,&nbsp;Hiroaki Iwamoto,&nbsp;Hiroshi Yaegashi,&nbsp;Shohei Kawaguchi,&nbsp;Takahiro Nohara,&nbsp;Kazuyoshi Shigehara,&nbsp;Atsushi Mizokami","doi":"10.1111/ajco.70051","DOIUrl":"10.1111/ajco.70051","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>To evaluate the real-world effectiveness of adjuvant nivolumab following radical surgery in patients with high-risk urothelial carcinoma, using historical data for comparison.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Patients who underwent radical surgery at our institution were retrospectively analyzed. They were divided into two groups: one group received adjuvant nivolumab, and the other received no adjuvant therapy. Oncological outcomes, adverse events, and treatment completion rates were assessed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 158 patients were included: 20 in the adjuvant nivolumab group and 138 in the control group. The median observation periods were 20.4 months in the nivolumab group and 36.7 months in the control group. The nivolumab group showed significantly improved recurrence-free survival compared to the control group (hazard ratio: 0.21; 95% confidence interval: 0.10–0.42; <i>p</i> = 0.01). Although overall survival tended to improve in the nivolumab group, the difference was not statistically significant (hazard ratio: 0.32; 95% confidence interval: 0.01–1.01; <i>p</i> = 0.22). Multivariate analysis confirmed adjuvant nivolumab as a significant favorable prognostic factor for recurrence-free survival (hazard ratio: 0.18; 95% confidence interval: 0.044–0.73; <i>p</i> = 0.017). One-year treatment was completed in 55.0% of patients. Adverse events led to discontinuation in 25.0%, with major events including interstitial lung disease (three patients), hormonal disorders such as isolated adrenocorticotropic hormone deficiency (2), rash (3), hypothyroidism (1), and hepatitis (1).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Adjuvant nivolumab demonstrated clinical benefit in Asian patients with high-risk urothelial carcinoma in a real-world setting.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 5","pages":"685-691"},"PeriodicalIF":2.1,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145494410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}